Relmada Therapeutics, Inc. (RLMD) Stock Grade

About Relmada Therapeutics, Inc.'s fundamentals

Relmada Therapeutics is a biotechnology company with a market capitalization of $397.5 million that reported no revenue growth year-over-year and generated no net income in its latest annual period, resulting in a net loss. The company does not pay a dividend and operates without profitable margins, which is typical for early-stage biotech firms still in development or commercialization phases. As a loss-making company, standard valuation metrics like P/E ratio and return on equity are not applicable.